American Freedom Elevate 7 review

Yes, for the right buyer. This is a good annuity for someone who has a genuine seven-year time horizon, wants a guaranteed rate with no index exposure, and values having their guarantee backed by a carrier with AM Best's top rating. It is less compelling for someone who wants a shorter commitment, a higher-upside growth vehicle, or income features built into the contract.

The main reason to buy American Freedom Elevate 7 is certainty over a seven-year period. You know the exact rate at purchase, the rate cannot be changed during the term, and there is no crediting complexity to monitor or manage. For someone rolling over a CD, a prior annuity, or a lump-sum distribution who wants predictability rather than potential, that simplicity has real appeal. The secondary reason is carrier strength — MassMutual Ascend is a subsidiary of Massachusetts Mutual Life, and the AM Best A++ rating is the highest available, which matters to buyers who prioritize the quality of the institution holding their money.

I think American Freedom Elevate 7 is best for someone in their mid-to-late accumulation years or early retirement — roughly 55 to 75 — who has money they are confident they will not need before the seven-year term ends. It is a natural fit for IRA or non-qualified money earmarked for a specific future purpose (retirement income, legacy, a property purchase) where timing lines up with the term. Buyers who fund at $100,000 or more get the higher rate tier, which makes the economics even cleaner. It is not the right fit for someone who has even a moderate chance of needing the principal early or who wants a chance at higher returns through index strategies.

You are buying a promise: MassMutual Ascend will hold your money for seven years and return it with a guaranteed rate of interest, nothing more. There are no index strategies, no participation rates, no caps to monitor. The contract credits interest at a fixed rate set on the day it is issued, and that rate is guaranteed for the full term. After the term ends, there is a 30-day window where you can surrender, renew, or transfer without penalty. If you stay beyond that window, a new rate is set by the company — it will be at least the contractual minimum, but there is no guarantee it will match the original rate. That renewal dynamic is an important detail for people who set and forget these contracts.

The crediting mechanism is about as simple as annuities get. On the issue date, the company declares a fixed interest rate. That rate is applied to your account value on an ongoing basis for the entire seven-year term. There are no allocation choices to make, no index performance to track, and no annual crediting anniversaries to watch. The rate is guaranteed not to change until the term expires.

The contract uses two rate bands based on purchase payment size. Contracts funded below $100,000 earned 4.65% at the rate date noted in the brochure materials; contracts funded at $100,000 or more earned 4.80%. These specific rates reflect a point-in-time snapshot and will vary with market conditions at the time of purchase. The structure — not the specific rate — is what the contract guarantees.

The most meaningful secondary feature is the Extended Care Waiver Rider and Terminal Illness Waiver Rider, both included at no additional charge. If you or a joint annuitant is confined to a qualified nursing facility for at least 90 consecutive days after the first contract year, surrender charges and the MVA are waived on withdrawals. A one-time terminal illness waiver is also available after the first contract year with an appropriate medical diagnosis. These provisions are not substitutes for long-term care coverage, but they do provide meaningful liquidity relief in scenarios where the usual penalty structure would otherwise make a withdrawal painful. The fact that they come at no cost makes them worth noting as a differentiator from stripped-down MYGA products that skip them. Note: these riders are not available in Massachusetts, and California uses a different but expanded version of these waivers.

This annuity is designed for long-term money, and you should treat it as a seven-year commitment. Free withdrawals are available up to 10% of purchase payments in year one and up to 10% of account value in subsequent years. Withdrawals above that are subject to surrender charges starting at 8% in years one and two and stepping down each year after. Crucially, a Market Value Adjustment (MVA) also applies to any withdrawal subject to surrender charges. The MVA can increase or decrease the effective penalty depending on the direction of interest rates relative to the rate environment when you purchased — if rates have risen since your issue date, the MVA adds additional cost on top of the printed charge.

Required minimum distributions attributable to this contract are exempt from surrender charges and MVA, which matters for buyers funding qualified accounts. The care and terminal illness waivers provide additional exit flexibility for serious health events. But outside of those carve-outs, early access is expensive, and the MVA exposure makes the total exit cost less predictable than a contract without one.

There are essentially no explicit fees on this contract. No base contract fee, no rider fee, no annual charge. The company earns its margin through the spread between what it makes on its investment portfolio and what it credits to you — that spread is baked into the declared rate, not layered on top as a separate fee line item. For buyers who want a simple, clean fee story, this design is appealing.

The real tradeoffs are structural, not fee-based. First, the seven-year term is longer than the mid-tier 5-year MYGAs that are popular in the market — you give up flexibility for the duration guarantee. Second, the MVA introduces genuine uncertainty about the total cost of an early exit, beyond the stated surrender charge. Third, the renewal rate after the term is not disclosed in advance and may be meaningfully lower than the initial rate. Buyers should think carefully about what they will do at the end of the seven-year term and should not assume the renewal rate will match the original.

Legal Entity: MassMutual Ascend Life Insurance Company

Parent: Massachusetts Mutual Life Insurance Company

AM Best Rating: A++